Truncated versions of the human cytomegalovirus (CMV) strain Towne glycoprotein B (gB) gene were stably expressed in CHO cell lines. The calcium-specific ionophore A23187 inhibited proteolytic cleavage of C-terminal-truncated gB expressed by cell line 67.77. These inhibition studies also showed that the 93-kilodalton cleavage product most likely represents the N-terminal cleavage fragment of gB. The ionophore carboxyl cyanide m-chlorophenyl-hydrazone was used to show that proteolytic cleavage of gB did not occur in the endoplasmic reticulum. Two-dimensional polyacrylamide gel electrophoresis demonstrated that the N-and C-terminal cleavage products of gB remained associated by disulfide linkages after cleavage. Expression studies using constructs in which 80% or all of the N terminus was deleted demonstrated that the N terminus was required for secretion of the gB molecule. The amino acid sequence at the site of cleavage was shown to be critical for cleavage by a cellular protease. Our results indicate that an arginine-to-threonine change at either amino acid 457 or 460, a lysine-to-glutamine change at amino acid 459, or all three substitutions together block gB cleavage. The effect on proteolysis of the arginine-to-threonine amino acid change at residue 457 (position -4 relative to the cleavage site) demonstrated that a basic pair of amino acids at the endoproteolytic processing site is not the only requirement in cis for gB cleavage.
Human cytomegalovirus (CMV) is a member of the herpesvirus group and is a significant cause of morbidity and mortality in certain human populations (reviewed by Ho; see reference 24) . CMV infections may take a severe course in congenitally infected newborns, in recurrent infection due to reactivation of latent virus, or in generalized infection as a consequence of prolonged immunosuppression (1, 16) . Because passively acquired antibodies have been shown to provide some protection against CMV disease (40, 42, 53, 59, 60, 61) , a subunit vaccine which would elicit a neutralizing-antibody response against CMV could be useful for prevention of the serious consequences of CMV disease. We and others have previously identified CMV glycoprotein B (gB) as a candidate antigen for inclusion in a subunit vaccine (12, 14, 21, 46, 52, 57) .
The gB complex is a major target for virus-neutralizing antibody both in the virus (4, 9, 12, 14, 35, 38, 46, 52, 57) and in complexes isolated from viral membrane preparations (17, 21-23, 27, 41) . These reports concur that the polypeptides being described are from the family of glycoproteins originally designated gA by Pereira et al. (45) and now identified as gB (14, 32, 36, 52) . The mature 55-kilodalton (kDa) gB glycoprotein, detected on extracellular virions (6, 34, 46) , is cleaved from the 130-kDa gB precursor at a specific processing site and represents the C-terminal half of the gp130 precursor (52) . This processing was predicted by pulse-chase experiments (10, 14, 46) and by use of Xgtll expression studies (36) . However, the identity or the fate of the Nterminal half of gB in CMV-infected cells has not been established.
The consensus sequence at the processing site of gB homologs that are cleaved is Arg-(Thr/Ser/Arg)-(Lys/Arg)-* Corresponding author.
Arg and is conserved among human herpesviruses (30, 52) . The basic amino acids near the cleavage sites of many viral glycoproteins appear to contribute to the structural requirements for cleavage (20, 44, 50, 51) . In particular, we have previously noted (52) the similarity of the herpesvirus processing sites to the processing sites of human immunodeficiency virus gp160 and the influenza virus hemagglutinin (HA) (18, 28, 29, 39, 58) . Endoproteolytic cleavage of CMV gB is mediated by a host cell enzyme (52) whose identity and intracellular location have not yet been established.
In this study, we have used recombinant forms of CMV gB to identify components of the gB complex and to clarify details of the processing of gB. Specifically, we have generated cell lines expressing three forms of gB: C-terminally truncated secreted gB; molecules specifically mutated near the proteolytic-processing site; and N-terminal deletion constructs. These cell lines were treated with various ionophores in experiments designed to examine the structural requirements for cleavage and secretion. Since the proteolytic cleavage of HA can be inhibited by the calcium-specific ionophore A23187 (31), we were interested in knowing whether proteolysis of CMV gB would be inhibited by the ionophore in cell lines expressing a C-terminal-truncated form of gB. These studies have demonstrated that A23187 could inhibit proteolytic cleavage of gB by these cells in a dose-dependent manner, resulting in the secretion of the 110-kDa truncated precursor. We have previously demonstrated that the 31-kDa cleavage product is derived from the C-terminal portion of gB (52) , and the studies with A23187 have been used to identify the N terminus as the 93-kDa cleavage product. The ionophore carboxyl cyanide m-chlorophenyl-hydrazone (CCCP) inhibits transit of proteins from the endoplasmic reticulum (ER) to the Golgi (3). We have used CCCP to examine the processing of gB and have found 40. that cleavage occurs later in the secretory pathway than the ER. Consistent with this observation, we have shown that monensin also blocked gB proteolysis. Finally, we demonstrated that the N-terminal sequences of gB are required to maintain a structure which is capable of being cleaved and secreted. Consistent with the findings in the influenza virus system (28), we also report that for CMV gB the amino acid sequence at the site of cleavage does affect the susceptibility of the molecule to be cleaved by a cellular protease.
MATERIALS AND METHODS
gB-expressing cell lines. Chinese hamster ovary (CHO) cell lines producing recombinant gB derivatives were generated as previously described (43, 52) . CHO cell line 67.77 is a 0.25 ,uM methotrexate-amplified derivative of cell line 9-14 (previously described by Spaete et al. [52] ), which was generated by cotransfection of the C-terminal-truncated gB construct pXgB8 ( Fig. 1) with a plasmid encoding the selectable dhfr gene (54) .
CHO cell line 126 was generated by transfection of CHO cells with plasmid pXgB22, a truncated form of gB in which the majority of the N-terminal domain (Thr-43 to Thr-411) has been deleted, as shown in Fig. 1 (Fig. 1B) which encodes the selectable dhfr gene, whose expression is promoted by the adenovirus major late promoter (54) . Expression of the gB derivative encoded by pXgB22 is driven by the murine CMV immediate early promoter/enhancer (15) , which was taken from pON402 (37) as a 1,370-bp HpaI-to-PstI fragment. All the transcriptional units in this construct are terminated by simian virus 40 polyadenylation signals. Plasmid pXgB24 was constructed by excising gB sequences from plasmid pXgB9 containing the full-length gB gene cloned as a 3.12-kilobase-pair EagI fragment. Plasmid pXgB9 is identical to pXgBll (52) except that the gB sequences are in the reverse orientation. The gB sequences (2,196 bp) were excised from pXgB9 by using the BamHI site in the polylinker and the unique XhoI site in gB previously used in the construction of pXgB8. This 2,202-bp BamHI-XhoI fragment was cloned into pMCMVAdhfr at Sall to produce a SalI-XhoI fusion at the 3' end of gB, and the 5' BamHI and SalI sites were filled with Klenow and ligated. This truncated gB molecule extends to Leu-680 (52) and is identical to that described for pXgB8 (52) , except that four additional amino acids (Asp-Leu-Asp-Lys) are derived from the polylinker in pMCMVAdhfr before the translation termination codon. Plasmid pXgB24 also differs from pXgB8 by including 153 bp of 5'-untranslated gB leader sequence, whereas pXgB8 contains 84 bp of the 5'-untranslated gB leader.
Plasmids pXgB24clvl, -clv2, -clv3, and -clv4 were generated by substituting a 309-bp BalI gB restriction fragment, which encodes mutated sequences specifying alternate amino acids at the proteolytic cleavage site, for the wild-type gB sequences. Polymerase chain reaction (48, 49) Polymerase chain reaction primer pairs used to generate the site-specific mutations specifying alternate amino acids at the endoproteolytic processing site of gB. The 5' oligonucleotide primers specifying mutated amino acids (shown above nucleotide sequence) for plasmids pXgB24clvl, -2, -3, and -4 are indicated as gBPC CLV1 through 4. The 3' primer, gBPC 333, was used in all amplifications. Oligonucleotide primers were synthesized on an Applied Biosystems 380A synthesizer as described previously (52) .
to generate the mutated sequences. The 309-bp Ball fragment was enzymatically amplified for 30 cycles by using the primer pairs shown in Fig. 2 . Double-stranded M13mpl8 DNA containing a 914-bp EcoRI-to-BgII gB fragment which spans the cleavage site was used as a template. The authenticity of the nucleotide changes was verified by sequencing each of the resulting clv mutant plasmids.
Ionophore studies. Processing of recombinant gB in the presence of the ionophore A23187 (Calbiochem, La Jolla, Calif.) was examined by growing cells 2 h before labeling in reinforced Eagle medium (REM) (2) lacking calcium chloride but with the ionophore. The cells were pulsed for 2 h with 250 ,uCi of [35S]methionine per ml and incubated in unlabeled medium for 4 h, and the supernatants were analyzed by radioimmunoprecipitation with MAb 15D8 followed by electrophoresis on 12% sodium dodecyl sulfate (SDS)-polyacrylamide gels as previously described (43) . For studies using the ionophore CCCP, cells were pulsed with 250 ,uCi of [35S]methionine per ml for 15 min in minimal essential medium containing 25 mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid) and 0.292 g of L-glutamine per liter and lacking glucose, nucleosides, and NaHCO3, without or with the addition of CCCP. Labeled supernatants were analyzed by radioimmunoprecipitation with MAb 15D8 and SDS-polyacrylamide gel electrophoresis (SDS-PAGE) as described previously (43 (52) .
RESULTS
The calcium-specific ionophore A23187 inhibits proteolytic cleavage of recombinant gB. CHO cell line 67.77 is a methotrexate-amplified (0.25 ,uM) derivative of line [9] [10] [11] [12] [13] [14] (52) which expresses a gB molecule truncated by the deletion of amino acids 681 to 907 at the C terminus. As we have described previously for line 9-14, the gB synthesized by line 67.77 is rapidly processed to a 110-kDa precursor which is proteolytically cleaved into 93-and 31-kDa molecules (Fig.  3, lane 1) . Cleavage is incomplete, and both the cleaved and uncleaved forms of gB are secreted by this cell line. The calcium-specific ionophore A23187 has been shown to inhibit the proteolytic cleavage of HA (31) . To with MAb 15D8, subjected to 12% SDS-PAGE, and autoradiographed as described previously (43) . Identical results were also obtained with MAb 27-156 (data not shown). The protein molecular mass standards are shown on the left of the autoradiogram in kilodaltons, and the sizes of the gB-specific molecules are indicated on the right.
strates that the 93-kDa fragment is viral in origin and eliminates the possibility that MAb 15D8 has coprecipitated a cellular 93-kDa molecule in the complex. Since we have previously identified the 31-kDa fragment as originating from the C terminus of gB (52) , taken together these experiments show that the 93-kDa fragment most probably represents the N terminus of gB.
To study the composition of the gB complex in its unreduced form, supernatants of cell line 67.77 prepared in the presence or absence of A23187 were immunoprecipitated with MAb 15D8 and analyzed without reduction by SDS-PAGE (Fig. 4) . Both immunoprecipitates contained a prominent radiolabeled protein with an apparent size of 160 kDa (lanes 1 and 2) which appeared to be noncleaved gB (Fig. 3,  lane 8 ). Untreated cells contained an additional gB band, of 140 kDa (Fig. 4, lane 1) , which is composed of the two disulfide-linked 93-and 31-kDa gB cleavage products, as discussed below.
Cleavage does not occur in the ER. The results of studies by other laboratories using the ionophore monensin (4, 11, 22, 47) , which blocks Golgi transit (26) , were conflicting with respect to the ability of monensin to inhibit endoproteolytic processing. Since monensin is known to block the transit of membrane vesicles from the Golgi to the cell surface, we wanted to examine earlier processing events in the endoplasmic reticulum (ER) by using a well-characterized inhibitor of transit, CCCP (3) . CCCP inhibitor that blocks all ATP-requiring protein transport from the ER to the Golgi (25) . CHO line 67.77 and a control line (5-5) were pulse-labeled for 15 min with [35S]methionine, and lysates were immunoprecipitated with MAb 15D8. When transit of gB to the Golgi is blocked by CCCP (Fig. 5) , endoproteolytic processing is inhibited, as indicated by the absence of the 93-and 31-kDa cleavage products in lanes 5, 7, and 9. The presence of the 93-and 31-kDa cleavage products in the radioimmunoprecipitated products of cells receiving no drug (Fig. 5, lane 1) Analysis of recombinant gB complexes. The relationship of the cleaved and the noncleaved recombinant gB molecules under both reducing and nonreducing conditions was examined by two-dimensional SDS-PAGE. Proteins lacking intermolecular disulfide cross-linkages often have identical relative mobilities (Mrs) under reducing and nonreducing conditions and fall on a diagonal line in the second-dimension gel. As expected, noncleaved truncated gB and its amino (gBN) and carboxyl (gBc) cleavage products were all present on the diagonal after reducing-reducing two-dimensional SDS-PAGE (Fig. 6B) . The apparent Mrs of these proteins separated under reducing conditions were 135 (truncated gB), 97 (gBN), and 35 kDa (truncated gBc). Under nonreducing conditions (Fig. 6A ), noncleaved truncated gB had an estimated Mr of 160 kDa and was again present on the diagonal, indicating that it is monomeric and does not have intermolecular disulfide linkages. In contrast, the gB cleavage products gBN and gBc were present below the diagonal and moved together in the first-dimension nonreducing gel as a 140-kDa, disulfide-linked complex. The apparent size of this complex is consistent with it being a heterodimer composed of the 97-and 35-kDa fragments. The different relative mobilities of these three forms of gB (i.e., noncleaved nonreduced gB, 160 kDa; cleaved nonreduced gB, 140 kDa; noncleaved reduced gB, 135 kDa) indicate that the conformation of gB strongly influences its migration during SDS-PAGE. This result is consistent with single-dimension separations on polyacrylamide gels (Fig. 4) .
The N terminus of gB is required for cJeavage and secretion.
To explore the structural requirements for proteolytic processing and secretion, CHO cell lines expressing a gB construct (pXgB22) in which 80% of the N-terminal domain of gB was deleted were generated in an attempt to isolate cell lines secreting this deleted gB molecule. This N-terminal deletion construct retains the signal sequence and proteolytic processing site (52) but lacks the transmembrane and cytoplasmic domains of gB (Fig. 1) . CHO line 126 is a representative of the cell lines generated with the pXgB22 construct which resulted in the highest gB expression levels. Western blot analysis of lysates from three cell lines expressing this gB construct revealed a 43-kDa gB molecule that was reactive with MAb (Fig. 7, lanes 1, 2, and 3 (Fig. 7, lane 4) . [35S]methionine-labeled gB, immunoprecipitated by MAb 15D8, was combined with unlabeled molecular mass markers (Sigma; SDS 6H) and separated under nonreducing conditions followed by reducing conditions (A) or under reducing conditions in both dimensions (B) . The second-dimension gel was stained with Coomassie brilliant blue to visualize the marker proteins and processed for fluorography (8) . Shown here is a fluorogram of the resulting gel. A single gel was used to separate the reduced and nonreduced samples in the first dimension; another single gel was used for separation in the second dimension. gB, gBN, and gBc denote the uncleaved, N-terminal, and C-terminal gB cleavage products, respectively. The relative mobilities (Mrs ) of the marker proteins used to determine the diagonal line are shown on the axis for both dimensions. The doublet appearance of gBN in panel B is due to its comigration with the unlabeled marker, phosphorylase b.
Because it appeared that secretion but not expression of the truncated gB derivative was impaired, we examined the reasons for the increased size of the 43-kDa molecule compared with the expected 31-kDa C-terminal cleavage product. The 43-kDa N-terminal-deleted gB molecule is 10 kDa larger than the 33-kDa primary translation product expected with the signal peptide cleaved but with no other proteolytic processing. However, glycosylation at the eight remaining N-linked glycosylation sites encoded in the 43-kDa molecule, as well as the contribution of 0-linked , and 61 (lane 3), which were generated by transfection of dihydrofolate reductase-deficient CHO cells (56) with gB expression plasmid pXgB22 (Fig. 1) , or from CHO cell line 67.77 (lane 4) and control cell line 5-5 (lane 5). Approximately 40 ,ug of total protein, as determined by Pierce protein assay (Pierce Chemical, Rockford, Ill.), was loaded per lane, and samples were subjected to 12% SDS-PAGE, transferred to a nitrocellulose filter, and probed with MAb 27-156 as described previously (52) . The protein molecular mass standards are shown in kilodaltons on the left, and the sizes of gB-specific expressed forms are shown on the right. glycosylation, could account for this discrepancy. Additionally, we did not know whether the expressed gB molecule was cleaved.
First, to examine the amount of glycosylation on the 43-kDa molecules, we treated lysates of lines 126 and 67.77 with N-glycanase alone and/or with N-neuraminidase and 0-glycan peptide hydrolase. N-Glycanase specifically hydrolyzes asparagine-linked oligosaccharides from glycoproteins. Neuraminidase hydrolyzes terminal N-or 0-acylneuraminic acids, and 0-glycan peptide hydrolase hydrolyzes the N-acetylgalactosamine disaccharide core joined to the glycoprotein in an 0-type linkage. After N-glycanase treatment, the C-terminal gB fragment migrates at 25 kDa for line 67.77 (Fig. 8, lane 1) and 33 kDa for line 126 (Fig. 8, lane 2), in agreement with the predicted size of the primary translation products. The mobilities of these molecules were not altered by 0-glycanase (data not shown). Since the gB expressed by line 126 has 20% of the N terminus, its inability, after deglycosylation, to comigrate with the appropriately processed gB of line 67.77 is most probably due to lack of proteolytic processing at the cleavage site. Thus, some structural requirement for cleavage has been altered by the N-terminal deletion in the pXgB22 construct (Fig. 1) .
The amino acid sequence at the proteolytic processing site does affect the susceptibility of gB to be cleaved by the cellular protease. The processing studies of Kawaoka and Webster (28, 29) have identified critical basic amino acids for cleavage activation of HA. We chose to alter similarly distributed basic amino acids at the site of proteolytic processing to test the effect of selected substitutions on the ability of gB to be cleaved. As described in Materials and Methods and shown in Fig. 9 , a series of four constructs were generated by using pXgB24 with the following substitutions: Thr for Arg at -1 (clvl) and -4 (clv3) relative to the point of cleavage, Gln for Lys at -2 (clv2), and all three substitutions simultaneously (clv4). These plasmid constructs, designated pXgB24clvl through 4, respectively, were used to generate stable CHO cell lines.
To examine the effect of the amino acid substitutions on a) (33) , and subjected to 12% SDS-PAGE. The proteins were electroblotted onto nitrocellulose and probed with MAb 27-156 as described previously (52) . Protein molecular mass standards are shown in kilodaltons on the left, and the predicted sizes of the deglycosylated gB molecules are shown on the right. the processing of gB, the four cell lines expressing clv mutant gB proteins were analyzed by radioimmunoprecipitation with MAb 15D8. All the clv mutant cell lines express a gB molecule which comigrates with the uncleaved form of gB expressed by wild-type CHO line 67.77 (Fig. 10) . Longer exposures of the autoradiogram shown in Fig. 10 revealed that a small proportion (less than 1%) of the gB expressed by each mutant line continues to be appropriately processed (data not shown). This indicates that substitutions for basic amino acids at or near the proteolytic processing site result in gB molecules that are almost completely resistant to 
The effect of mutations near the gB cleavage site on the endoproteolytic processing of gB. Row 1 shows four amino acids on either side of the Towne gB endoproteolytic cleavage site as previously depicted (52) . Rows 2 to 5 show the comparable regions of cleavage (clv) mutant expression plasmids. The ability of the molecule to be cleaved by the cellular protease is indicated by + or -(see Fig. 10 ). The subscript numbers refer to the amino acid position within the gB protein sequence (52) . Arrow indicates the known proteolytic processing site. Asterisks denote amino acid sequence changes from the wild-type sequence shown in row 1. proteolysis. These data also confirm the A23187 processing data.
DISCUSSION
In this study, we have shown that the calcium-specific ionophore A23187 inhibits the endoproteolytic processing of CMV gB. Moreover, by using the ionophore CCCP, which inhibits translocation from the ER, we demonstrated that cleavage does not occur at that site. Analysis of the gB complex by using two-dimensional gel electrophoresis showed that the N-terminal 93-kDa fragment remains associated with the 31-kDa C-terminal fragment after proteolytic processing and that truncated, uncleaved gB is monomeric. We also showed that the N-terminal domain of gB is necessary to maintain correct processing and secretion, suggesting the necessity of structural requirements beyond the simple presence of a proteolytic processing site. Finally, we showed that for CMV gB, the amino acid sequence at the site of cleavage does affect the susceptibility of the molecule to be cleaved by cellular protease.
We have established the identity of the cleavage products encoded by the CMV gB gene. Because A23187 inhibits the proteolytic cleavage of gB in a dose-dependent manner, we were able to use the ionophore to establish the relationship of the cleavage products to the precursor and thus establish the identity of the N terminus of the processed gB molecule as the 93-kDa cleavage product. This cleavage fragment is immunoprecipitated by MAbs 15D8 and 27-156 as part of a complex which includes the truncated C-terminal cleavage fragment, gp3l, which is analogous to gp55 in virus-infected cells (52) . The ionophore A23187 may also prove to be a valuable reagent in assessing the requirements of a processed gB for viral infectivity. The inhibition of gB cleavage by the ionophore A23187 suggests that a calcium-dependent 1 (5, 19) . The calcium dependence of KEX2 (19) and the cellular protease which cleaves gB also supports this hypothesis. Earlier work in the influenza virus system with A23187 (31) established the neutral pH optimum and the nonlysosomal origin of the cellular cleavage enzyme in MDBK cells.
Previous results from other laboratories which examined the effects of monensin on processing (4, 11, 22, 47) had left open to question the formal possibility that processing occurs even earlier than the cis Golgi. Our result obtained with the ionophore CCCP showed that proteolytic processing occurs subsequent to the ER. Recently, Bennet et al. (7) have indicated that cleavage of HA appears to be initiated either during transport vesicle formation in the trans Golgi network or during transit of the trans Golgi vesicle. Our results using various ionophores and our results showing that specific amino acid sequence changes near the processing site interfere with cleavage suggest that these features of the processing of CMV gB are shared with HA in the influenza virus system and that the cellular location where processing occurs is probably the same.
Two-dimensional gel electrophoresis was used to show that the noncleaved truncated gB molecule does not have intermolecular disulfide linkages and that the N-terminal and C-terminal cleavage products remain associated by disulfide linkages, implying that cleavage occurs after the molecule has folded. These findings are compatible with earlier interpretations of the structure of gB complexes (6, 10, 17, 22, 46) .
We generated a CHO cell line expressing a construct (pXgB22) in which 80% of the N terminus is deleted in order to express the C-terminal region of the gB molecule encoding a majority of the currently recognized neutralizing epitopes (4, 52, 57) . We have also constructed a eucaryotic expression vector in which the 660-base-pair C-terminal gB fragment was fused to the tissue plasminogen activator signal sequence, which has been shown to facilitate the synthesis and secretion of human immunodeficiency virus type 1 gp120 (N. Haigwood, personal communication) and fragments of Factor VIlIc (13) . When tested in transient expression assays in COS-7 cells, secretion but not expression was impaired, in agreement with the results described above for the pXgB22 construct (data not shown). These results suggest a block in the secretion pathway which correlates with the absence of N-terminal sequences in both the constructs.
The inability to obtain secretion of truncated gB with two different N-terminal deletion constructs tested indicates that the N terminus provides some essential structural requirement for secretion. The results obtained with the ionophore A23187 demonstrate that blocking proteolytic cleavage is not an impediment to secretion. This result is germane to the case of the pXgB22 construct expressed in CHO line 126, in which 80% of the N terminus is deleted and the expressed, nonsecreted protein is not cleaved. More probably, inappropriate folding or deletion of 7 of the 11 cysteine residues remaining after signal peptidase cleavage has altered the structure of this version of gB.
Finally, following the lead provided by Kawaoka and Webster (28, 29) 
